ReviewProstate cancer and prostatic diseases2002
The potential role of bisphosphonates in prostate cancer.
Review in Prostate cancer and prostatic diseases, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 53 citations in OpenAlex.
- Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.The Cochrane database of systematic reviews · 2020Pooled it
- Calcium Phosphate Cements as Carriers of Functional Substances for the Treatment of Bone Tissue.Materials (Basel, Switzerland) · 2023Review
- Osteoclasts directly influence castration-resistant prostate cancer cells.Clinical & experimental metastasis · 2022Article
- What are the efficacy and safety of bisphosphonates and RANK-ligand-inhibitors for men with prostate cancer and bone metastases? - A Cochrane Review summary with commentary.Journal of musculoskeletal & neuronal interactions · 2021Article
- Extracellular Vesicle-Mediated Bone Remodeling and Bone Metastasis: Implications in Prostate Cancer.Sub-cellular biochemistry · 2021Review
- Therapeutic Dimensions of Bisphosphonates: A Clinical Update.International journal of preventive medicine · 2020Review
- Humanized bone facilitates prostate cancer metastasis and recapitulates therapeutic effects of zoledronic acid in vivo.Bone research · 2019Article
- High-throughput cancer hypothesis testing with an integrated PhysiCell-EMEWS workflow.BMC bioinformatics · 2018Article
- Article
- MicroRNA Exert Macro Effects on Cancer Bone Metastasis.Current osteoporosis reports · 2016Review
- Article
- Targeting Bone Metastases in Metastatic Castration-Resistant Prostate Cancer.Clinical Medicine Insights. Oncology · 2016Review
- Zoledronate can promote apoptosis and inhibit the proliferation of colorectal cancer cells.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2015Article
- Radium-223 for the treatment of castration-resistant prostate cancer.OncoTargets and therapy · 2015Review
- Current treatments and novel therapeutic targets for castration resistant prostate cancer with bone metastasis.American journal of clinical and experimental urology · 2013Review
- Bone-targeted therapies in metastatic castration-resistant prostate cancer: evolving paradigms.Prostate cancer · 2013Review
- Alendronate decreases orthotopic PC-3 prostate tumor growth and metastasis to prostate-draining lymph nodes in nude mice.BMC cancer · 2008Article
- Bone metabolism and new targets for intervention.Current urology reports · 2007Review
- Urologic skeletal metastases: current diagnostic and treatment strategies.Current urology reports · 2007Article
- Contemporary agents in the management of metastatic castration-resistant prostate cancer.Canadian Urological Association journal = Journal de l'Association des urologues du CanadaReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Skeletal morbidity secondary to metastases and osteoporosis is common in patients with advanced prostate cancer. Despite the typically sclerotic nature of prostate cancer metastases, osteoclast mediated osteolysis may play a significant role. This review addresses the newly recognised antitumour effects of bisphosphonates in addition to their role in inhibiting osteoclast mediated bone resorption. Both preclinical and clinical evidence of a role for bisphosphonates in the treatment and prevention of bone metastases secondary to prostate cancer is assessed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.